Quantcast

Latest Bristol-Myers Squibb Stories

2014-03-18 23:33:25

Rapid CYP2C19 Testing for Personalized Antiplatelet Therapy in 600-Patient Clinical Trial with Spartan Bioscience (PRWEB) March 18, 2014 Spartan Bioscience today announced the start of a 600-patient study of personalized medicine for cardiac stent patients in Germany. The study is part of a larger clinical trial entitled “Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes Trial (TROPICAL-ACS)”. TROPICAL-ACS, led by principal...

2014-03-18 08:32:43

-- ABRAXANE plus gemcitabine approved by the TGA for the first-line treatment of metastatic pancreatic cancer MELBOURNE, Australia, March 18, 2014 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved...

2014-03-17 08:29:58

SAN DIEGO, March 17, 2014 /PRNewswire/ -- Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has changed its corporate name and business to Taxus Cardium Pharmaceuticals Group Inc. in connection with its strategic collaboration and funding arrangement concluded with China-based Shanxi Taxus Pharmaceuticals Co., Ltd. http://photos.prnewswire.com/prnvar/20140317/LA83695LOGO The strategic collaboration is designed to support the commercial development of Generx(®) and...

2014-03-13 08:28:11

CALGARY, March 13, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2014. "In 2013, we reported data from a number of clinical studies, which included our first data correlating specific biomarkers with survival in NSCLC lung cancer patients and culminated with the reporting of our first randomized data in head and neck cancer," said...

2014-03-06 08:32:02

LAS VEGAS, March 6, 2014 /PRNewswire/ - Vansen Pharma Inc. [OTCQB: VNSN] is pleased to announce the appointment of Mr. Ali Moghaddam to its Board of Advisors. Mr. Moghaddam is an accomplished pharmaceutical executive with over 25 years of experience in both Canada and the U.S., having played a transformational role with companies such as Bristol- Myers Squibb Canada, Linson Pharma Inc. (generic business unit of BMS), Allergan Canada, and E-Z-EM Inc. U.S. (now part of Bracco Group)....

2014-03-06 08:29:53

SAN DIEGO, March 6, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present a comparison of the pharmacokinetic (PK) properties of Cynviloq and nab-paclitaxel (Abraxane(®)) at the 31(st )Annual Miami Breast Cancer Conference in Miami Beach, Florida. Highlights of the findings include new and historical data on PK bioequivalence of...

2014-03-03 16:25:40

SAN DIEGO and PARSIPPANY, N.J., March 3, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of The Medicines Company (NASDAQ: MDCO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between February 20, 2013 and February 12, 2014 (the "Class...

2014-02-25 23:30:10

Company Strengthens its Market Presence in Europe San Francisco, CA (PRWEB) February 25, 2014 Viscira®, a leading provider of interactive, new-media communication solutions and software products for the life sciences industry, today announced the opening of a new office in London. This destination will serve as a launching point for the company to expand its business in the top five European markets (France, Germany, Italy, Spain, and the United Kingdom) and beyond. This move...

2014-02-24 08:29:54

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Ambrx Inc. today announced that Sheila Gujrathi, M.D., has joined its board of directors. Dr. Gujrathi is currently the chief medical officer at Receptos (Nasdaq: RCPT) where she is responsible for the clinical development of therapeutic candidates for the treatment of immune and metabolic diseases. "Sheila is an industry veteran with significant experience in immunologic and oncologic drug development," said Lawson Macartney, Ph.D., chief...

2014-02-20 08:32:02

Data Support Ongoing Randomized Phase 2 Study in Recurrent or Metastatic Head and Neck Cancer SEATTLE, Feb. 20, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. announced today the presentation of clinical data of VTX-2337, a cancer immunotherapy, in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) at the 2014 Multidisciplinary Head and Neck Cancer Symposia in Scottsdale, Arizona. Results indicate that the...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.